Companies researching Ocrevus (ocrelizumab)

Ocrevus (ocrelizumab) is a humanized anti‑CD20 monoclonal antibody employed as an immunosuppressive therapy for multiple sclerosis.

List of companies that research Ocrevus (ocrelizumab)

CompanyCountryIndustryEmployeesRevenueTechnologies
Country flag

Australia

Hospitals and Health Care

730

Ocrevus (ocrelizumab)

Country flag

United States

Higher Education

13k

$2.3B

Ocrevus (ocrelizumab)

Country flag

United States

Hospitals and Health Care

51

$2M

Ocrevus (ocrelizumab)

Country flag

Switzerland

Biotechnology Research

104k

$68B

Ocrevus (ocrelizumab)

Country flag

United States

Hospitals and Health Care

201

Ocrevus (ocrelizumab)

Country flag

United Kingdom

Hospitals and Health Care

193k

$105B

Ocrevus (ocrelizumab)

Country flag

United States

Hospitals and Health Care

6.3k

$300M

Ocrevus (ocrelizumab)

Country flag

United States

Biotechnology Research

21k

$26B

Ocrevus (ocrelizumab)

Country flag

United States

Professional Services

2.7k

$400M

Ocrevus (ocrelizumab)

Country flag

United States

IT Services and IT Consulting

201

$27M

Ocrevus (ocrelizumab)

Showing top companies out of 32 that research Ocrevus (ocrelizumab). Get the full list on TheirStack.

Frequently asked questions